Ehtesham Moneeb, Mapara Khubaib Y, Stevenson Charles B, Thompson Reid C
Department of Neurological Surgery, Vanderbilt University Medical Center, 21st Avenue & Garland Street, Nashville, TN 37232, USA.
Cancer Lett. 2009 Feb 18;274(2):305-12. doi: 10.1016/j.canlet.2008.09.034. Epub 2008 Nov 12.
Increasing evidence points to a fundamental role for cancer stem cells (CSC) in the initiation and propagation of many tumors. As such, in the context of glioblastoma multiforme (GBM), the development of treatment strategies specifically targeted towards CSC-like populations may hold significant therapeutic promise. To this end, we now report that the cell surface chemokine receptor, CXCR4, a known mediator of cancer cell proliferation and invasion, is overexpressed in primary glioblastoma progenitor cells versus corresponding differentiated tumor cells. Furthermore, administration of CXCL12, the only known ligand for CXCR4, stimulates a specific and significant proliferative response in progenitors but not differentiated tumor cells. Taken together, these results implicate an important role for the CXCR4 signaling mechanism in glioma CSC biology and point to the therapeutic potential of targeting this pathway in patients with GBM.
越来越多的证据表明,癌症干细胞(CSC)在许多肿瘤的起始和增殖过程中发挥着重要作用。因此,在多形性胶质母细胞瘤(GBM)的背景下,针对类似CSC群体的治疗策略的开发可能具有重大的治疗前景。为此,我们现在报告,细胞表面趋化因子受体CXCR4,一种已知的癌细胞增殖和侵袭的介质,在原发性胶质母细胞瘤祖细胞中相对于相应的分化肿瘤细胞过度表达。此外,给予CXCR4唯一已知的配体CXCL12,可刺激祖细胞而非分化肿瘤细胞产生特异性且显著的增殖反应。综上所述,这些结果表明CXCR4信号机制在胶质瘤CSC生物学中具有重要作用,并指出了针对该通路治疗GBM患者的潜力。